Ocular Therapeutix Announces Exercise of Over-Allotment Option

BEDFORD, Mass.--()--Ocular Therapeutix (Nasdaq: OCUL), a biopharmaceutical company focused on the development and commercialization of innovative therapies for diseases and conditions of the eye, announced today that the underwriters of its initial public offering have exercised in full their over-allotment option to purchase an additional 750,000 shares at the initial public offering price of $13.00 per share, less underwriting discounts. After giving effect to the over-allotment closing, the total number of shares sold by Ocular Therapeutix in its initial public offering increased to 5,750,000 shares, which resulted in gross proceeds of approximately $74.8 million and net proceeds of approximately $66.5 million after deducting underwriting discounts and estimated offering expenses.

Morgan Stanley, Cowen and Company and RBC Capital Markets acted as joint book-running managers for the offering. Oppenheimer & Co. acted as a co-manager. A copy of the final prospectus relating to the offering may be obtained from Morgan Stanley & Co. LLC, attention: Prospectus Department, 180 Varick Street, 2nd Floor, New York, New York 10014; Cowen and Company, LLC, c/o Broadridge Financial Services, attention: Prospectus Department, 1155 Long Island Avenue, Edgewood, NY, 11717; or RBC Capital Markets, LLC, attention: Equity Syndicate, Three World Financial Center, 200 Vesey Street, 8th Floor, New York, NY 10281-8098.

A registration statement relating to these securities was declared effective by the Securities and Exchange Commission on July 24, 2014. This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities, in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

About Ocular Therapeutix

Ocular Therapeutix, Inc. is a biopharmaceutical company focused on the development and commercialization of innovative therapies for diseases and conditions of the eye using its proprietary hydrogel platform technology. Ocular Therapeutix’s lead product candidates are in Phase 3 clinical development for post-surgical ocular inflammation and pain, and Phase 2 clinical development for glaucoma, ocular hypertension and allergic conjunctivitis. The Company is also evaluating sustained-release injectable anti-VEGF drug depots for back-of-the-eye diseases. Ocular Therapeutix’s first product, ReSure® Sealant, is FDA-approved to seal corneal incisions following cataract surgery.

Contacts

Investors:
Ocular Therapeutix, Inc.
Brad Smith
Chief Financial Officer
bsmith@ocutx.com
or
Burns McClellan on behalf of Ocular Therapeutix
Kimberly Minarovich, 212-213-0006
kminarovich@burnsmc.com
or
Media:
Scott Corning
Vice President of Sales and Marketing
scorning@ocutx.com

Release Summary

Ocular Therapeutix (Nasdaq: OCUL) IPO underwriters exercised in full their over-allotment option to purchase an additional 750,000 shares, resulting in gross proceeds of approximately $74.8 million.

Sharing

Contacts

Investors:
Ocular Therapeutix, Inc.
Brad Smith
Chief Financial Officer
bsmith@ocutx.com
or
Burns McClellan on behalf of Ocular Therapeutix
Kimberly Minarovich, 212-213-0006
kminarovich@burnsmc.com
or
Media:
Scott Corning
Vice President of Sales and Marketing
scorning@ocutx.com